RBC Capital analyst Leonid Timashev maintained a Buy rating on Pyxis Oncology (PYXS – Research Report) on March 18 and set a price target of ...

In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on Pyxis Oncology (PYXS – Research Report). The company’s ...

William Blair issued their FY2027 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, ...

Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a report ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. | Having recently trimmed back its pipeline to a sole cancer candidate, ...

Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at ...

So, the natural question for Pyxis Oncology (NASDAQ:PYXS) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative ...

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that ...

Pyxis Oncology BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers ...

So, the natural question for Pyxis Oncology (NASDAQ:PYXS) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free ...

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced ...

BOSTON - Pyxis Oncology , Inc. (NASDAQ:PYXS), a clinical-stage biopharmaceutical company with a market capitalization of $71 million, has been granted Fast Track Designation by the U.S. Food and Drug ...